Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Cenicriviroc46 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00838 | 34951993 | Gastroenterology | Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. | 2021 | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | 2021 | Details |
| A03482 | 33987427 | Ann Transl Med | Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. | 2021 | Details |
| A03484 | 33987424 | Ann Transl Med | Non-alcoholic fatty liver diseases: current challenges and future directions. | 2021 | Details |
| A03845 | 33849361 | Expert Opin Drug Discov | The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. | 2021 | Details |
| A04097 | 33761646 | Medicine (Baltimore) | The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. | 2021 | Details |
| A04749 | 33515800 | Ann Hepatol | Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. | 2021 | Details |
| A05080 | 33385317 | J Dig Dis | Efficacy and safety of drugs for nonalcoholic steatohepatitis. | 2021 | Details |
| A05119 | 33368954 | Diabetes Obes Metab | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. | 2021 | Details |
| A05376 | 33278029 | Pharmacotherapy | Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. | 2021 | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | 2020 | Details |
| A06057 | 33025657 | Liver Int | Recent advances targeting C-C chemokine receptor type 2 for liver diseases in monocyte/macrophage. | 2020 | Details |
| A07203 | 32583961 | Clin Transl Sci | Evolving Role for Pharmacotherapy in NAFLD/NASH. | 2020 | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08581 | 32052857 | Hepatology | New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. | 2020 | Details |
| A08905 | 31943293 | Hepatology | Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. | 2020 | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | 2020 | Details |
| A09084 | 31881392 | Contemp Clin Trials | Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. | 2019 | Details |
| A09473 | 31731005 | Contemp Clin Trials | A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. | 2019 | Details |
| A10083 | 31495973 | Hepatol Res | Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. | 2019 | Details |
| A12052 | 30622370 | World J Gastroenterol | Role of cenicriviroc in the management of nonalcoholic fatty liver disease. | 2018 | Details |
| A12835 | 30261763 | Expert Rev Gastroenterol Hepatol | An update on the recent advances in antifibrotic therapy. | 2018 | Details |
| A13470 | 29956213 | Adv Exp Med Biol | Current Prevention and Treatment Options for NAFLD. | 2018 | Details |
| A14360 | 29448843 | Expert Opin Investig Drugs | Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. | 2018 | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | 2017 | Details |
| A14850 | 29204050 | World J Gastroenterol | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | 2017 | Details |
| A15013 | 29128056 | Clin Liver Dis | Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. | 2017 | Details |
| A15375 | 28940700 | Hepatology | Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. | 2018 | Details |
| A15580 | 28833331 | Hepatology | A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. | 2018 | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | 2016 | Details |
| A18110 | 27347680 | PLoS One | Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. | 2016 | Details |
| A18671 | 27003143 | Dig Dis Sci | Novel Pharmacotherapy Options for NASH. | 2016 | Details |
| A18784 | 26944023 | Contemp Clin Trials | Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. | 2016 | Details |
| A30155 | 32884369 | Hepat Med | Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data. | 2020 | Details |
| A30847 | 31680767 | Korean J Physiol Pharmacol | Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. | 2019 | Details |
| A31571 | 30271738 | J Clin Transl Hepatol | Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. | 2018 | Details |
| A31816 | 29765319 | Front Pharmacol | Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. | 2018 | Details |
| A31819 | 29761169 | Hepatol Commun | Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. | 2018 | Details |
| A43317 | 31985310 | Expert Opin Investig Drugs | Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH). | 2020 | Details |
| A43342 | 31952447 | Expert Opin Investig Drugs | Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. | 2020 | Details |
| A47009 | 30179264 | Hepatology | Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice. | 2019 | Details |
| A47734 | 32739404 | Antiviral Res | The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. | 2020 | Details |
| A47987 | 27169903 | Clin Transl Sci | Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment. | 2016 | Details |
| A49464 | 35744024 | Medicina (Kaunas) | An Update on the Chemokine System in the Development of NAFLD. | 2022 | Details |
| A49865 | 35614896 | Visc Med | Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. | 2021 | Details |
| A51305 | 35749425 | PLoS Pathog | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. | 2022 | Details |